ABEO
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 6.93 · operating margin -1537% — readings disagree
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
VENTE TOTALE: 15 000 titres (~87 966,00 $ US)
- Insiders
- Alvino Mark
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$87,966
Avg sell (VWAP, 90d window) $6.77 vs last close —
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-01 | Alvino Mark | Sell | 15,000 | $5.86 | $87,966 | Form 4 |
| 2026-07-21 | Vazzano Joseph Walter | Sell | 1,478 | $6.53 | $9,651 | Form 4 |
| 2026-07-09 | O'Malley Brendan M. | Sell | 12,050 | $6.96 | $83,913 | Form 4 |
| 2026-07-09 | Seshadri Vishwas | Sell | 67,971 | $6.96 | $473,330 | Form 4 |
| 2026-07-09 | Vasanthavada Madhav | Sell | 12,606 | $6.96 | $87,784 | Form 4 |
| 2026-07-09 | Vazzano Joseph Walter | Sell | 24,880 | $6.96 | $173,257 | Form 4 |
| 2026-06-30 | Alland Leila | Sell | 11,000 | $5.92 | $65,087 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-09-03
Despite ABEO's encouraging liquidity score (85) and early-stage profitability turnaround, the near-zero catalyst score (10) driven by insider selling, active litigation investigations, and a Q2 earnings miss…
The first sentence of the analysis written for ABEO on 2026-09-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 73.7% | 0.0% | 54.1% | 68.2% | 100.0% | |
| Ebit Margin | 1289.1% | 0.0% | -1536.3% | -2755.3% | -2709.3% | |
| Ebitda Margin | 1350.3% | 0.0% | -1444.9% | -2431.6% | -2560.5% | |
| Operating Profit Margin | -1536.9% | 0.0% | -1346.7% | -3600.8% | -2994.5% | |
| Pretax Profit Margin | 1224.8% | 0.0% | -1548.2% | -2807.4% | -2831.2% | |
| Continuous Operations Profit Margin | 1223.1% | 0.0% | -1548.2% | -2807.4% | -2831.2% | |
| Net Profit Margin | 1223.1% | 0.0% | -1548.2% | -2807.4% | -2831.2% | |
| Bottom Line Profit Margin | 1152.5% | 0.0% | -1548.2% | -3074.8% | -2831.2% | |
| Current Ratio | 6.930 | 6.080 | 4.153 | 6.826 | 3.386 | |
| Quick Ratio | 6.744 | 6.080 | 4.153 | 6.826 | 3.386 | |
| Solvency Ratio | 1.238 | -0.937 | -1.037 | -0.938 | -2.162 | |
| Cash Ratio | 2.653 | 1.408 | 1.078 | 1.828 | 1.981 | |
| Price To Earnings Ratio | 3.933 | -3.594 | -1.980 | -0.557 | -0.395 | |
| Price To Earnings Growth Ratio | -0.021 | 0.093 | 0.037 | 0.007 | 0.072 | |
| Forward Price To Earnings Growth Ratio | -0.021 | 0.093 | 0.037 | 0.007 | 0.072 | |
| Price To Earnings Diluted Ratio | 5.218 | -3.594 | -1.980 | -0.557 | -0.395 | |
| Price To Earnings Diluted Growth Ratio | -0.032 | 0.093 | 0.037 | 0.007 | 0.072 | |
| Price To Book Ratio | 1.753 | 5.193 | 7.225 | 0.905 | 0.790 | |
| Price To Sales Ratio | 47.949 | 0.000 | 30.604 | 17.125 | 11.158 | |
| Price To Free Cash Flow Ratio | -3.310 | -3.911 | -2.869 | -0.555 | -0.479 | |
| Price To Operating Cash Flow Ratio | -3.656 | -4.082 | -2.894 | -0.557 | -0.510 | |
| Debt To Assets Ratio | 0.114 | 0.212 | 0.084 | 0.119 | 0.118 | |
| Debt To Equity Ratio | 0.157 | 0.523 | 0.364 | 0.285 | 0.221 | |
| Debt To Capital Ratio | 0.136 | 0.344 | 0.267 | 0.222 | 0.181 | |
| Long Term Debt To Capital Ratio | 0.047 | 0.228 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.379 | 2.474 | 4.317 | 2.400 | 1.878 | |
| Working Capital Turnover Ratio | 0.045 | 0.000 | 0.080 | 0.033 | 0.063 | |
| Operating Cash Flow Ratio | -2.581 | -3.377 | -2.757 | -5.590 | -3.950 | |
| Operating Cash Flow Sales Ratio | -13.114 | 0.000 | -10.574 | -30.752 | -21.888 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.104 | 1.044 | 1.009 | 1.003 | 1.063 | |
| Debt Service Coverage Ratio | 4.917 | -5.587 | -120.986 | -46.716 | -21.011 | |
| Interest Coverage Ratio | -23.917 | -15.259 | -112.763 | -69.178 | -24.572 | |
| Short Term Operating Cash Flow Coverage Ratio | -6.245 | -9.452 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -3.057 | -2.430 | -6.854 | -5.701 | -7.002 | |
| Capital Expenditure Coverage Ratio | -9.571 | -22.901 | -111.810 | -334.485 | -15.819 | |
| Dividend Paid And Capex Coverage Ratio | -9.571 | -22.901 | -111.810 | -334.485 | -15.819 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 2.871 | -4.033 | -1.939 | -0.513 | -0.129 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 73.7% | ▲73.7% | ▲14.5% |
| Ebit Margin | 1289.0% | ▲1289.0% | ▲2431.4% |
| Ebitda Margin | 1350.3% | ▲1350.3% | ▲2367.6% |
| Operating Profit Margin | -1536.9% | ▼-1536.9% | ▲358.9% |
| Pretax Profit Margin | 1224.8% | ▲1224.8% | ▲2417.2% |
| Continuous Operations Profit Margin | 1223.1% | ▲1223.1% | ▲2415.8% |
| Net Profit Margin | 1223.1% | ▲1223.1% | ▲2415.8% |
| Bottom Line Profit Margin | 1152.5% | ▲1152.5% | ▲2412.9% |
| Current Ratio | 6.929 | ▲0.849 | ▲1.455 |
| Quick Ratio | 6.744 | ▲0.663 | ▲1.306 |
| Solvency Ratio | 1.238 | ▲2.176 | ▲2.006 |
| Cash Ratio | 2.653 | ▲1.244 | ▲0.863 |
| Price To Earnings Ratio | 3.933 | ▲7.526 | ▲4.452 |
| Price To Earnings Growth Ratio | -0.021 | ▼-0.114 | ▼-0.059 |
| Forward Price To Earnings Growth Ratio | -0.021 | ▼-0.114 | ▼-0.059 |
| Price To Earnings Diluted Ratio | 5.218 | ▲8.811 | ▲5.479 |
| Price To Earnings Diluted Growth Ratio | -0.032 | ▼-0.124 | ▼-0.067 |
| Price To Book Ratio | 1.753 | ▼-3.440 | ▼-1.420 |
| Price To Sales Ratio | 47.949 | ▲47.949 | ▲26.582 |
| Price To Free Cash Flow Ratio | -3.310 | ▲0.601 | ▼-1.085 |
| Price To Operating Cash Flow Ratio | -3.656 | ▲0.425 | ▼-1.316 |
| Debt To Assets Ratio | 0.114 | ▼-0.098 | ▼-0.015 |
| Debt To Equity Ratio | 0.157 | ▼-0.367 | ▼-0.153 |
| Debt To Capital Ratio | 0.136 | ▼-0.208 | ▼-0.094 |
| Long Term Debt To Capital Ratio | 0.047 | ▼-0.182 | ▼-0.008 |
| Financial Leverage Ratio | 1.379 | ▼-1.095 | ▼-1.111 |
| Working Capital Turnover Ratio | 0.045 | ▲0.045 | ▲0.001 |
| Operating Cash Flow Ratio | -2.581 | ▲0.796 | ▲1.070 |
| Operating Cash Flow Sales Ratio | -13.114 | ▼-13.114 | ▲2.151 |
| Free Cash Flow Operating Cash Flow Ratio | 1.105 | ▲0.061 | ▲0.060 |
| Debt Service Coverage Ratio | 4.917 | ▲10.504 | ▲42.794 |
| Interest Coverage Ratio | -23.917 | ▼-8.657 | ▲25.221 |
| Short Term Operating Cash Flow Coverage Ratio | -6.245 | ▲3.207 | ▼-3.106 |
| Operating Cash Flow Coverage Ratio | -3.057 | ▼-0.627 | ▲1.952 |
| Capital Expenditure Coverage Ratio | -9.571 | ▲13.330 | ▲89.346 |
| Dividend Paid And Capex Coverage Ratio | -9.571 | ▲13.330 | ▲89.346 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 2.871 | ▲6.903 | ▲3.619 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $279.1M | $228.6M | $107.1M | $24.2M | $33.5M | |
| Enterprise value | $225.6M | $228.3M | $98.0M | $17.6M | $9.9M | |
| EV / Sales | 38.76x | 0.00x | 28.01x | 12.46x | 3.30x | |
| EV / Op. cash flow | -2.96x | -4.08x | -2.65x | -0.41x | -0.15x | |
| EV / Free cash flow | -2.68x | -3.91x | -2.63x | -0.40x | -0.14x | |
| EV / EBITDA | 2.87x | -4.03x | -1.94x | -0.51x | -0.13x | |
| Net debt / EBITDA | -0.68x | 0.01x | 0.18x | 0.19x | 0.31x | |
| Current ratio | 6.93x | 6.08x | 4.15x | 6.83x | 3.39x | |
| Income quality | -1.07x | 0.88x | 0.68x | 1.09x | 0.77x | |
| Graham number | $10 | — | — | — | — | |
| Graham net-net | $3 | $1 | $0 | $2 | $3 | |
| Tax burden | 99.9% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 95.0% | 107.1% | 100.8% | 101.9% | 104.5% | |
| Working capital | $175.3M | $84.3M | $42.3M | $45.3M | $39.7M | |
| Invested capital | $189.2M | $92.2M | $50.3M | $56.4M | $62.8M | |
| Return on assets | 32.4% | -58.5% | -84.7% | -61.8% | -106.7% | |
| Operating ROA | -54.5% | -74.3% | -73.5% | -70.8% | -77.9% | |
| Return on tangible assets | 32.4% | -58.5% | -84.7% | -61.8% | -108.6% | |
| Return on equity | 44.7% | -144.7% | -365.5% | -148.3% | -200.5% | |
| Return on invested capital | -44.0% | -64.8% | -91.4% | -87.5% | -138.7% | |
| Return on capital employed | -47.1% | -69.5% | -93.2% | -90.2% | -142.7% | |
| Earnings yield | 25.5% | -27.9% | -50.6% | -163.9% | -253.7% | |
| Free cash flow yield | -30.2% | -25.6% | -34.9% | -180.1% | -208.6% | |
| Capex / Op. cash flow | -10.4% | -4.4% | -0.9% | -0.3% | -6.3% | |
| Capex / Depreciation | 223.8% | 84.1% | 10.4% | 2.8% | 93.0% | |
| Capex / Sales | 137.0% | 0.0% | 9.5% | 9.2% | 138.4% | |
| SG&A / Sales | 1117.4% | 0.0% | 543.0% | 1220.4% | 721.5% | |
| R&D / Sales | 460.7% | 0.0% | 888.3% | 2048.4% | 1290.9% | |
| Stock comp / Sales | 185.2% | 0.0% | 136.2% | 215.8% | 297.2% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 1.7% | |
| Days sales outstanding | 421d | 0d | 255d | 49d | 365d | |
| Days payables outstanding | 1880d | 432d | 423d | 1469d | 0d | |
| Operating cycle | 1730d | 0d | 255d | 49d | 365d | |
| Cash conversion cycle | -150d | -432d | -168d | -1420d | 365d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+22.1%EV / Sales n/aEV / EBITDA ▲+171.2%EV / Op. cash flow ▲+1.121Earnings yield ▲+0.534
Profitability
Return on equity ▲+1.895Return on assets ▲+0.909Return on invested capital ▲+0.208Return on capital employed ▲+0.225Operating ROA ▲+0.198Income quality ▼-1.951Tax burden ▼-0.001
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+1447.511Operating cycle n/aCash conversion cycle ▲+282.330Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.849Net debt / EBITDA ▼-0.686Working capital ▲+91070000.000Invested capital ▲+96971000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+733.7%EV / Sales ▲+1073.1%EV / EBITDA ▲+2324.5%EV / Op. cash flow ▼-2.805Earnings yield ▲+2.793
Profitability
Return on equity ▲+2.452Return on assets ▲+1.391Return on invested capital ▲+0.947Return on capital employed ▲+0.956Operating ROA ▲+0.234Income quality ▼-1.845Tax burden ▼-0.001
Efficiency
Days sales outstanding ▲+56.130Days payables outstanding n/aOperating cycle ▲+1364.841Cash conversion cycle ▼-514.719Capex / Sales ▼-0.013R&D / Sales ▼-8.302
Balance-sheet strength
Current ratio ▲+3.543Net debt / EBITDA ▼-0.987Working capital ▲+135667000.000Invested capital ▲+126424000.000Intangibles / Total assets ▼-0.017
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-09-03 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).
- 2026-09-02 Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2026:
- 2026-09-01 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 2026-09-01 Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-08-27 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 2026-08-13 Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity Abeona Therapeutics reported Q2 revenues of $11.4m, treating five Zevaskyn patients, but missed analyst expectations, leading to a 14% stock drop. Operational setbacks in Zevaskyn''s rollout, including cancellations and manufacturing issues, highlight a steep learning curve, but management expects improvement as experience grows. Partnered programs with Ultragenyx and Taysha offer potential near-term catalysts, with milestone and royalty payments possible if approvals and sales targets are met.
- 2026-08-13 Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript
- 2026-08-13 Abeona Therapeutics Q2 Earnings Call Highlights Abeona Therapeutics NASDAQ: ABEO reported second-quarter revenue growth from its ZEVASKYN cell therapy launch while outlining operational challenges involving patient scheduling and manufacturing that affected revenue recognition.
- 2026-08-13 Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update - Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments completed – - Expanding QTC network now includes seven sites nationwide; growing number of QTCs progressing patients through treatment process – - $146.8 million in cash, cash equivalents and short-term investments as of June 30, 2026 – CLEVELAND, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2026 and provided an update on commercial execution for ZEVASKYN (prademagene zamikeracel). Commercial Update Steady launch-year growth for ZEVASKYN.
- 2026-08-06 Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company will host a conference call on Thursday, August 13, 2026 at 8:30 a.m. ET to discuss its financial results for the second quarter of 2026 and provide a corporate update.